These are the people who want to buy 23andMe

The spitting in a test tube, send it to the silicon valley, then sit and wait for information about your grandparents and genetic health risks. For more than 15 million people, a 23andme test once looked like a good idea.

For about 80 % of customers, their interaction with the company went further – they chose to use their data in health research. Thus, 23andme collected one of the largest DNA databases in the world, with aspirations to see all these DNA threads one day offering new medical breakthroughs.

But many 23ndme customers began to rethink the wisdom of DNA sharing with the company in 2023, when infiltrators stormed their database and accessing detailed information about nearly 7 million people. After that, last week, 23andme submitted bankruptcy, which led to a comprehensive panic and warnings that customers should delete their data from the site before selling its assets.

Amid calls for an equal organization on how private companies use personal data, 23andme tried to reassure customers that they are doing everything in their power to prevent their data from falling into the wrong hands. In an open letter, he wrote that Chapter 11 file “does not change how to store, manage or protect customer data” and pledge that privacy will be “important considerations in any treatment.” But this did not stop speculation about where the data might fall after the May 14 auction.

On March 31, the US Federal Trade Committee was writing a letter to the agency, which oversees bankruptcy, saying that whoever buys 23andme should be bound by the same privacy agreement as the current policy of the company. Among other things, the company promised customers that it will not share any information with employers or health insurance companies unless they have their linear consent.

So far, only a few parties publicly interested are known that they are interested in buying 23andme, along with their huge data collection. Here’s a look at four potential buyers:

Nucleius Genome

Nucleus is a full -headed Genome test company in New York and is supported by investors such as Thiel, which is led by Thiel, and the founder of Reddit Alexis Ohanian. Nucleus CEO, Nucleus, has launched the possibility of buying 23ndme several months ago, and reconsidering the idea now after the company applied for bankruptcy.

Sadeghi is called Nucleus the Netflix to Blockbuster’s 23andme, indicating that the next repetition of the genome test because it covers the entire genomics using a newer technology. On its website, Nucleus states that all customer data “will be used and shared according to HIPAA requirements.”

Nucleus offers customers of $ 400 that you say can determine healthy risks to more than 900 cases. But the company also attracted a controversy from launching and defending the genetic intelligence test, which is no longer available on the site.

Sadeghi says luck It is more than others on 23ndme data, but for Lemonaid, the health care company from the remote bought by 23andme in 2021. He wants to start integrating the genome test and practicing health care, which is just 23andme. “There is a much greater chance here, first and foremost, you realize the power of the genome,” Sadigue says.

SEI Foundation

SEI, a non -profitable organization dedicated to the leadership of the adoption of a high -speed SEI platform, says it sees an opportunity to bankrupt 23ndme to show how Blockchains and decentralized networks can be used for more than just encoded currency transactions.

The Foundation is a deski defender, which is short for decentralized science, and it is a movement to make scientific research more transparent and cooperative. In a post on X, she recently described a vision to buy 23andme, put millions of data points on Blockchain, and returned it to her original owners “through encrypted secret transportation.” The Foundation says that its plan will allow people to control “how to liquidate their data and share it in revenue.”

Elianor Davis, President of Disi at the SEI Foundation, says that the organization considers itself the ideal 23ndme buyer when it comes to protecting the privacy of data and combining the “decentralized science movement ethics” and rich 23ndme data.

Justin Barlo, head of business development, adds that this application will be fully compatible with health data and privacy laws.

“The relevant legal issues are not characterized by whether the data is stored on the series or not, and the current policy requires new notice and approvals from customers in the event of the sale of assets or change in control,” said Gerald Gallagher, General Adviser to the Foundation.

summit

Ryan Citton, CEO and founder of the Benkal Analysis Company, was up to buy 23ndme before he was submitted to bankruptcy. In an online publication that deals with the company’s shareholders, he said that he would buy a genetic test company for $ 100 million, that is, more than an offer from former CEO Ann Wajiki who was in front of the company.

“[W]”We believe that our algorithms associated with your data can give people more ideas about their long -term health than ever.”

Citton, a businessman, engineer, and former Republican politician who was the Commissioner of the Railways Committee in Texas, did not make an official offer at that time, but he told luck He sees a great opportunity for the United States to reduce health care costs using genetic tests. He said that giving people information about their health risks allows them to focus on prevention, adding: “I think this is this kind of things that can change the world.”

Since the bankruptcy of 23andme, a Pinnacle spokesman said that the private company “is discussing our way forward and still has a dangerous interest” in the data test.

Ann Wajiki

Anne Wogiki, 23andme and its former CEO, resigned on the same day that he presented biotechnology for bankruptcy. But she made it clear that she did not leave exactly. Instead, you still hope to revive the company by purchasing it itself. “I have resigned as a CEO of the company so that I could be in the best position to follow up on the company as an independent bidding,” she wrote.

A WoJCICKI spokesman refused to provide any other comment.

WoJCICKI 23ANDME has led 19 years old and is seen as a pioneer in genetic medicine. However, the company once from $ 6 billion did not become profitable.

Previous CEO tried to buy the company twice before. Her first invasion ended for the private, with a proposal that the council considers very low and not funded properly, when all the former members of the Board of Directors resigned on the same day. In early March, WoJCICKI set a second proposal to buy the company and submit it to its new younger council. This offer was also rejected.

“We have achieved many successes, but I am on an equal footing of the challenges we face today,” Wiki wrote in her post on the day when she resigned. “There is no doubt that the challenges faced by 23andme through an advanced business model were real, but my faith in the company and its future is not shaken.”

This story was originally shown on Fortune.com

2025-04-01 17:19:00